secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2023-09-08T23:59:59+00:00
Accession:  0001193125-23-231669
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Magenta Therapeutics stockholders approve merger with Dianthus; closing expected Sept 11
--------------------------------------------------------------------------------

- Stockholders approved share issuance and change of control (30.1M For, 6.3M Against) and reverse stock split (47.4M For).
- Reverse stock split ratio range 1:10 to 1:18; final ratio determined by mutual board agreement.
- Officer exculpation amendment not approved (30.0M For, 3.4M Against, 2.98M Abstentions).
- Merger closing expected on or around Sept 11, 2023; post-closing co. to operate as Dianthus Therapeutics (DNTH).
- Three Class II directors elected: Jeffrey Albers, Anne McGeorge, David Scadden.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523231669/0001193125-23-231669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523231669/d515463d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-231669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer